EarlyDx is committed to providing cutting-edge non-invasive genomics technologies and best-in-class early disease diagnostics. Our proprietary cfDNA-based technologies, in combination with powerful AI algorithms, have shown great potential to transform non-invasive biomarker discovery, diagnostics, and precision medicine for almost any diseases, including cancers, aging, metabolic diseases, autoimmune diseases, imprinting diseases, and neurological diseases.
Our key cfDNA-based best-in-class technologies include:
1. cfMethyl-seq: a powerful and cost-effective NGS solution to profile the cfDNA methylome
2. cfSNV: a cutting-edge computational tool to accurately call mutations directly from blood
3. cfTrack: for non-invasive monitoring of cancer MRD, recurrence, and evolution
4. EarlyDx-Cloud: a comprehensive bioinformatics data analysis platform for liquid biopsy
Please check out our relevant publications in details: https://earlydx.com/technologies/publications/
Company Details
- Employees
- 9
- Founded
- -
- Address
- 570 Westwood Plaza,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.earlydx.com
- Keywords
- Cancer Diagnostics, cfDNA, Methylome, Liquid Biopsy, Biomarker, Companion Diagnostics, Disease Early Detection.
- HQ
- Los Angeles, California
Earlydiagnostics Questions
Earlydiagnostics's website is https://www.earlydx.com
Earlydiagnostics's LinkedIn profile is https://www.linkedin.com/company/earlydx
Earlydiagnostics has
9 employees.
View email and phone details for 9
employees at Earlydiagnostics.
Earlydiagnostics's industry is
Biotechnology Research
Earlydiagnostics's top competitors are
Femsync,
Rarefied Biosciences,
Sera Prognostics,
Reflodx, Inc.,
Pléiade & Cie,
Terra Bio,
Element Biosciences,
Lunglife Ai,
Vibrojet™ Technologies,
Translational Software.
Earlydiagnostics's categories are Biotechnology Research
Earlydiagnostics's founding year is 2017
